Why 22q11.2 deletion syndrome is the appropriate population for this question
The chromosomal microdeletion at 22q11.2 affects approximately 1 in 3,000-6,000 live births and produces a wide phenotype spanning cardiac anomalies, palatal abnormalities, immune deficits, and—most relevant here—a substantially elevated risk for psychiatric illness. McDonald-McGinn et al.’s 2015 Nature Reviews Disease Primers review documents that roughly 25% of individuals with 22q11.2DS develop schizophrenia or related psychotic disorders by adulthood, compared to a baseline population risk of approximately 1%. The deletion is therefore the strongest known molecularly defined genetic risk factor for schizophrenia, and 22q11.2DS cohorts have become a privileged population for studying the developmental trajectory from genetic risk to manifest psychotic illness.
A specific feature of that trajectory makes prevention research tractable. Vorstman, Breetvelt, and colleagues (2015) showed in a multi-site analysis published in JAMA Psychiatry that cognitive decline—particularly in verbal IQ—precedes psychosis onset in 22q11.2DS by months to years. Children and adolescents with the deletion who will go on to develop psychosis show trajectories of declining cognitive performance during the prodromal period; those who will not develop psychosis show stable trajectories. This pre-onset cognitive change is one of the most reliable phenotypic markers available for identifying which 22q11.2DS individuals are progressing toward psychotic illness, and it provides a measurable target for any intervention claiming to alter the developmental course.
The Mancini et al. study design
The 2021 paper is a retrospective cohort study drawing on the Geneva 22q11.2DS longitudinal program. The sample comprised 98 participants with confirmed 22q11.2 deletion, followed at 2 to 4 longitudinal time points across an age range of 10 to 32 years. Three subgroups were compared:
- n = 30 participants with no psychiatric diagnoses and no psychotropic medication (the within-syndrome reference group);
- n = 30 participants who developed psychotic symptoms but did not receive SSRI treatment (the at-risk untreated group);
- n = 38 participants who received SSRI treatment, primarily for mood or anxiety disorder indications.
Three primary outcomes were tracked across follow-up: full-scale IQ from age-appropriate Wechsler scales, cortical thickness from structural MRI, and hippocampal volume. The analytic strategy compared longitudinal trajectories across the three groups using mixed-effects models that account for repeated measurements and uneven follow-up timing.
The retrospective nature of the design is the central methodological constraint. SSRI prescription was clinically indicated rather than randomly assigned, so participants in the SSRI-treated group differ systematically from untreated participants in ways that include the indication for SSRIs (mood/anxiety symptoms) and parental and clinical decisions about treatment. The authors handle this confound by comparing the SSRI-treated group not to a hypothetical “ideal control” but to the at-risk-untreated group whose 22q11.2DS-related symptomatology would have made SSRIs reasonable but for whatever clinical or contextual reason did not receive them. The comparison is informative but does not have the causal cleanness of a randomized trial.
The cognitive trajectory finding
The primary result on IQ trajectory is that SSRI-treated participants showed stable or modestly improving IQ over follow-up, while at-risk untreated participants showed the declining trajectory characteristic of 22q11.2DS-associated psychosis prodrome. Critically, the SSRI-treated group included individuals who developed psychotic symptoms—not only those whose mood/anxiety symptoms remained the primary clinical concern. The cognitive protective effect, in other words, did not depend on participants remaining symptom-free during the follow-up; it appeared even among SSRI-treated individuals whose psychotic-spectrum symptoms developed during the observation window.
This dissociation between symptomatic course and cognitive trajectory is the part of the result with the strongest implications. If the cognitive decline preceding psychosis is itself a marker of pathological brain change—reduced synaptic plasticity, hippocampal atrophy, prefrontal dysmaturation—then attenuating the cognitive decline implies attenuating the underlying neurodevelopmental change. The structural brain findings the authors report are consistent with this interpretation.
The structural brain findings
SSRI-treated participants showed greater cortical thickness in frontal regions and greater hippocampal volume compared to the at-risk untreated group, with effect magnitude inversely correlated with age at SSRI onset. Participants who started SSRIs in early adolescence showed the largest structural differences relative to the untreated comparison group; participants who started in late adolescence or early adulthood showed smaller differences.
Two interpretations of this gradient are plausible. The first is a sensitive-period account: SSRIs administered during the period of active cortical and hippocampal development confer larger structural benefits because the neural substrate is more responsive to neurotrophic and serotonergic signaling at that age. The second is a cumulative-exposure account: participants who started earlier accumulated longer SSRI exposure by the time of structural assessment, and the structural difference reflects total exposure rather than timing per se. The retrospective design cannot fully separate these explanations, but the pattern is consistent with both serotonergic-developmental literatures.
The hippocampal-volume finding is particularly notable because hippocampal atrophy is a documented feature of 22q11.2DS-associated psychosis. Subsequent work in the Geneva and other 22q11.2DS cohorts has linked emerging psychotic symptoms to dysmaturation of hippocampal functional connectivity and to excitatory-inhibitory imbalance underlying hippocampal atrophy. If SSRIs increase hippocampal volume in this population, the mechanism most likely involves promotion of neurogenesis in the dentate gyrus and protection against stress-induced hippocampal damage—both serotonin-mediated processes documented in animal models of antidepressant action.
Mechanism candidates
The Mancini et al. (2021) result does not directly identify a mechanism, but the candidate mechanisms are well-characterized. Serotonergic regulation of neuroplasticity is the most parsimonious account: SSRIs increase synaptic serotonin, which acts at 5-HT1A and other receptors to up-regulate brain-derived neurotrophic factor (BDNF) and to promote dendritic spine formation and adult neurogenesis. HPA-axis dampening is a second pathway: SSRIs reduce stress-induced cortisol elevations, which in animal models is sufficient to protect hippocampal neurons from stress-related atrophy. Anti-inflammatory effects are a third candidate: SSRIs have documented immunomodulatory properties, and 22q11.2DS is associated with immune dysregulation that may contribute to psychiatric phenotypes.
Whether any single mechanism dominates the observed cognitive and structural effects in this specific population is unknown. The 22q11.2 deletion produces hemizygosity for several genes (COMT, TBX1, DGCR8 among others) that influence dopaminergic and serotonergic signaling in ways that may interact with SSRI action specifically in this genetic context. Mechanistic dissection in 22q11.2DS-relevant model systems is the appropriate next step.
What the study cannot establish
First, the design is retrospective and observational. The SSRI-treated and untreated groups differ in clinical and parental factors that influenced prescription decisions, and these factors may themselves be associated with cognitive and brain outcomes through pathways unrelated to SSRI pharmacology. Causal interpretation requires randomized confirmation.
Second, the population is highly specific. 22q11.2DS confers an unusually elevated psychosis risk through a defined molecular mechanism, and the cognitive and brain findings observed here may not generalize to non-22q11.2 high-risk populations (clinical high risk based on symptom criteria, family history, or polygenic risk). Whether SSRI prescription is similarly neuroprotective in those populations is a separate empirical question.
Third, a clinical concern not in the paper’s own limitations section but worth flagging is the standard contraindication of SSRIs in early adolescence based on the FDA black-box warning regarding suicidality risk. Any clinical translation of these findings would need to weigh the cognitive-protective signal against established acute-risk concerns and the broader literature on pediatric SSRI safety, which has been actively debated for over two decades.
Implications for psychosis prevention research
The conventional pharmacological approach to high-risk-for-psychosis populations has emphasized antipsychotic medication, with mixed results: some trials show modest delay or attenuation of psychotic symptoms, but cognitive outcomes have been less encouraging and side-effect burden is substantial. The Mancini et al. (2021) findings suggest that SSRIs—a medication class with comparatively favorable safety profiles in adolescent populations—may merit dedicated study as candidate neuroprotective interventions in psychosis prevention research.
The appropriate next step is a prospective, ideally randomized, study in 22q11.2DS or other defined high-risk populations comparing SSRI exposure to placebo or treatment-as-usual on cognitive trajectory, structural brain measures, and psychotic-symptom outcomes. Such a trial faces ethical and recruitment challenges given the long follow-up needed to capture meaningful psychiatric outcomes, but the genetic-syndrome high-risk framing makes the trial-population identification unusually tractable: 22q11.2DS is detected in routine clinical genetics, and longitudinal follow-up infrastructure exists in several international cohorts.
The deeper conceptual contribution of the 2021 paper is to shift the framing of SSRIs from symptom-suppressive medications for diagnosed mood/anxiety disorders to candidate disease-modifying agents in neurodevelopmental psychiatric risk. That shift is consistent with broader literatures on serotonergic regulation of neurogenesis and on early-intervention approaches in psychosis prevention. Whether the specific empirical claim about 22q11.2DS replicates will determine whether the conceptual shift is supported; the existing data justify the next round of studies to find out.
Frequently asked questions
What is 22q11.2 deletion syndrome?
22q11.2 deletion syndrome is a chromosomal microdeletion affecting approximately 1 in 3,000–6,000 live births. It produces a wide phenotype spanning cardiac anomalies, palatal abnormalities, immune deficits, and elevated psychiatric risk. About 25% of individuals with the deletion develop schizophrenia or related psychotic disorders by adulthood, compared to roughly 1% in the general population, making it the strongest known molecularly defined genetic risk factor for schizophrenia.
What did Mancini et al. (2021) find?
Long-term SSRI treatment in children and adolescents with 22q11.2 deletion syndrome was associated with stable or modestly improving IQ trajectories, greater cortical thickness in frontal regions, and greater hippocampal volume—compared to at-risk untreated participants who showed the declining trajectory characteristic of the 22q11.2DS-associated psychosis prodrome. Effect magnitude was inversely correlated with age at SSRI onset.
Why is cognitive decline a target for psychosis prevention research?
Vorstman et al. (2015) showed that cognitive decline—particularly in verbal IQ—precedes psychosis onset in 22q11.2DS by months to years. Children and adolescents who go on to develop psychosis show declining cognitive trajectories during the prodromal period; those who do not develop psychosis show stable trajectories. Cognitive decline is therefore a measurable target for any intervention claiming to alter the developmental course toward psychotic illness.
What mechanisms could explain a neuroprotective effect of SSRIs?
Three candidate mechanisms are well-characterized. SSRIs increase synaptic serotonin, which up-regulates BDNF and promotes dendritic spine formation and adult neurogenesis. They dampen HPA-axis activation, reducing stress-induced cortisol elevations that in animal models drive hippocampal neuron atrophy. They have documented anti-inflammatory effects, which may interact with the immune dysregulation characteristic of 22q11.2DS.
Can these findings be generalized beyond 22q11.2 deletion syndrome?
Not directly. 22q11.2DS confers psychosis risk through a defined molecular mechanism with hemizygosity for genes (COMT, TBX1, DGCR8) that influence dopaminergic and serotonergic signaling. Whether SSRI exposure is similarly neuroprotective in non-22q11.2 high-risk populations (defined by clinical symptoms, family history, or polygenic risk) is a separate empirical question.
What are the limits of the evidence?
The design is retrospective and observational; SSRI prescription was clinically indicated rather than randomly assigned, so the treated and untreated groups differ in clinical and parental factors that may independently affect outcomes. Causal interpretation requires randomized confirmation. The FDA black-box warning regarding suicidality risk in pediatric SSRI use also constrains any clinical translation pending dedicated prospective trials.
References
- Mancini, V., Maeder, J., Bortolin, K., Schneider, M., Schaer, M., & Eliez, S. (2021). Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.2 deletion syndrome. Translational Psychiatry, 11(1), 336. https://doi.org/10.1038/s41398-021-01456-x
- McDonald-McGinn, D. M., Sullivan, K. E., Marino, B., Philip, N., Swillen, A., Vorstman, J. A. S., Zackai, E. H., Emanuel, B. S., Vermeesch, J. R., Morrow, B. E., Scambler, P. J., & Bassett, A. S. (2015). 22q11.2 deletion syndrome. Nature Reviews Disease Primers, 1, 15071. https://doi.org/10.1038/nrdp.2015.71
- Vorstman, J. A. S., Breetvelt, E. J., Duijff, S. N., Eliez, S., Schneider, M., Jalbrzikowski, M., Armando, M., Vicari, S., Shashi, V., Hooper, S. R., Chow, E. W. C., Fung, W. L. A., Butcher, N. J., Young, D. A., McDonald-McGinn, D. M., Vogels, A., van Amelsvoort, T., Gothelf, D., Weinberger, R., … Bassett, A. S. (2015). Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. JAMA Psychiatry, 72(4), 377-385. https://doi.org/10.1001/jamapsychiatry.2014.2671